<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Key Company ", fill: "#aaf0d1"},
{source: "3: Key Company ", target: "3: products generate", fill: "#aaf0d1"},
{source: "3: products generate", target: "3: significant amount", fill: "#aaf0d1"},
{source: "3: significant amount", target: "3: Companys ", fill: "#aaf0d1"},
{source: "3: Companys ", target: "3: cash flows", fill: "#aaf0d1"},
{source: "3: cash flows", target: "3: adversely affect", fill: "#aaf0d1"},
{source: "3: adversely affect", target: "3: leading products could", fill: "#aaf0d1"},
{source: "3: leading products could", target: "3: negative impact on", fill: "#aaf0d1"},
{source: "3: negative impact on", target: "3: operations", fill: "#aaf0d1"},
{source: "3: Key Company ", target: "4: The Companys ", fill: "#00703c"},
{source: "4: The Companys ", target: "4: generate profits", fill: "#00703c"},
{source: "4: generate profits", target: "4: cash flow", fill: "#00703c"},
{source: "4: cash flow", target: "4: dependent upon", fill: "#00703c"},
{source: "4: dependent upon", target: "4: increasing profitability", fill: "#00703c"},
{source: "4: increasing profitability", target: "4: Companys ", fill: "#00703c"},
{source: "4: Companys ", target: "4: cholesterol", fill: "#00703c"},
{source: "4: cholesterol", target: "4: franchise consisting", fill: "#00703c"},
{source: "4: franchise consisting", target: "4: VYTORIN and ZETIA In ", fill: "#00703c"},
{source: "4: VYTORIN and ZETIA In ", target: "4: addition products such as", fill: "#00703c"},
{source: "4: The Companys ", target: "5: of the Companys ", fill: "#7df9ff"},
{source: "5: of the Companys ", target: "5: dependence on key products", fill: "#7df9ff"},
{source: "5: dependence on key products", target: "5: adversely affect", fill: "#7df9ff"},
{source: "5: adversely affect", target: "5: products could", fill: "#7df9ff"},
{source: "5: products could", target: "5: significant impact on", fill: "#7df9ff"},
{source: "5: significant impact on", target: "5: operations", fill: "#7df9ff"},
{source: "5: of the Companys ", target: "6: patent protection increased costs", fill: "#ef3038"},
{source: "6: patent protection increased costs", target: "6: associated with manufacturing", fill: "#ef3038"},
{source: "6: associated with manufacturing", target: "6: availability", fill: "#ef3038"},
{source: "6: availability", target: "6: Companys ", fill: "#ef3038"},
{source: "6: Companys ", target: "6: competitive product", fill: "#ef3038"},
{source: "6: competitive product", target: "6: discovery", fill: "#ef3038"},
{source: "6: discovery", target: "6: previously unknown", fill: "#ef3038"},
{source: "6: previously unknown", target: "6: competition", fill: "#ef3038"},
{source: "6: competition", target: "6: introduction", fill: "#ef3038"},
{source: "6: introduction", target: "6: effective", fill: "#ef3038"},
{source: "6: effective", target: "6: treatments", fill: "#ef3038"},
{source: "6: treatments", target: "6: discontinuation", fill: "#ef3038"},
{source: "6: discontinuation", target: "6: removal from", fill: "#ef3038"},
{source: "6: patent protection increased costs", target: "7: specifically", fill: "#ffb7c5"},
{source: "7: specifically", target: "7: profitability", fill: "#ffb7c5"},
{source: "7: profitability", target: "7: Companys ", fill: "#ffb7c5"},
{source: "7: Companys ", target: "7: cholesterol", fill: "#ffb7c5"},
{source: "7: cholesterol", target: "7: franchise may", fill: "#ffb7c5"},
{source: "7: franchise may", target: "7: adversely affected by", fill: "#ffb7c5"},
{source: "7: adversely affected by", target: "7: generic forms", fill: "#ffb7c5"},
{source: "7: generic forms", target: "7: two competing cholesterol products", fill: "#ffb7c5"},
{source: "7: two competing cholesterol products", target: "7: will lose patent protection", fill: "#ffb7c5"},
{source: "7: specifically", target: "8: addition generic", fill: "#d99058"},
{source: "8: addition generic", target: "8: fluticasone propionate", fill: "#d99058"},
{source: "8: fluticasone propionate", target: "8: may unfavorably impact", fill: "#d99058"},
{source: "8: may unfavorably impact", target: "8: corticosteroid nasal spray market", fill: "#d99058"},
{source: "8: addition generic", target: "9: recent years", fill: "#faebd7"},
{source: "9: recent years", target: "9: adversely affected", fill: "#faebd7"},
{source: "9: adversely affected", target: "9: leading products", fill: "#faebd7"},
{source: "9: leading products", target: "9: particularly", fill: "#faebd7"},
{source: "9: particularly", target: "9: intense competition", fill: "#faebd7"},
{source: "9: intense competition", target: "9: prescription", fill: "#faebd7"},
{source: "9: prescription", target: "9: CLARITIN OTC ", fill: "#faebd7"},
{source: "9: CLARITIN OTC ", target: "9: US in December ", fill: "#faebd7"},
{source: "9: US in December ", target: "9: introduction", fill: "#faebd7"},
{source: "9: introduction", target: "9: Allegra ", fill: "#faebd7"},
{source: "9: Allegra ", target: "9: fexofenadine", fill: "#faebd7"},
{source: "9: fexofenadine", target: "9: US in September ", fill: "#faebd7"},
{source: "9: recent years", target: "10: addition as", fill: "#f0fff0"},
{source: "10: addition as", target: "10: introduction", fill: "#f0fff0"},
{source: "10: introduction", target: "10: competitors product", fill: "#f0fff0"},
{source: "10: competitors product", target: "10: interferon", fill: "#f0fff0"},
{source: "10: interferon", target: "10: generic ribavirin", fill: "#f0fff0"},
{source: "10: generic ribavirin", target: "10: PEGINTRON ", fill: "#f0fff0"},
{source: "10: PEGINTRON ", target: "10: ribavirin combination therapy", fill: "#f0fff0"},
{source: "10: ribavirin combination therapy", target: "10: hepatitis", fill: "#f0fff0"},
{source: "10: hepatitis", target: "10: been severely diminished", fill: "#f0fff0"},
{source: "10: been severely diminished", target: "10: cash flow", fill: "#f0fff0"},
{source: "10: cash flow", target: "10: been materially", fill: "#f0fff0"},
{source: "10: been materially", target: "10: negatively impacted", fill: "#f0fff0"},
{source: "10: addition as", target: "11: funds invested", fill: "#f0f"},
{source: "11: funds invested", target: "11: research will", fill: "#f0f"},
{source: "11: research will", target: "11: development", fill: "#f0f"},
{source: "11: development", target: "11: novel drugs", fill: "#f0f"},
{source: "11: novel drugs", target: "11: significant expenditures with", fill: "#f0f"},
{source: "11: significant expenditures with", target: "11: low probability", fill: "#f0f"},
{source: "11: funds invested", target: "12: failure inherent", fill: "#d6cadd"},
{source: "12: failure inherent", target: "12: treat diseases", fill: "#d6cadd"},
{source: "12: failure inherent", target: "17: development may fail", fill: "#a020f0"},
{source: "17: development may fail", target: "17: reach market", fill: "#a020f0"},
{source: "17: reach market", target: "17: numerous reasons", fill: "#a020f0"},
{source: "17: numerous reasons", target: "17: ineffectiveness", fill: "#a020f0"},
{source: "17: ineffectiveness", target: "17: preclinical testing", fill: "#a020f0"},
{source: "17: preclinical testing", target: "17: necessary regulatory approvals", fill: "#a020f0"},
{source: "17: necessary regulatory approvals", target: "17: new products", fill: "#a020f0"},
{source: "17: new products", target: "17: new indications", fill: "#a020f0"},
{source: "17: new indications", target: "17: economic feasibility due", fill: "#a020f0"},
{source: "17: economic feasibility due", target: "17: manufacturing costs", fill: "#a020f0"},
{source: "17: manufacturing costs", target: "17: proprietary rights", fill: "#a020f0"},
{source: "17: development may fail", target: "18: Intellectual ", fill: "#556b2f"},
{source: "18: Intellectual ", target: "18: important contributor", fill: "#556b2f"},
{source: "18: important contributor", target: "18: Companys ", fill: "#556b2f"},
{source: "18: Companys ", target: "18: profitability", fill: "#556b2f"},
{source: "18: profitability", target: "18: as patents covering", fill: "#556b2f"},
{source: "18: as patents covering", target: "18: Companys ", fill: "#556b2f"},
{source: "18: Companys ", target: "18: invalid generic forms", fill: "#556b2f"},
{source: "18: invalid generic forms", target: "18: Companys ", fill: "#556b2f"},
{source: "18: Companys ", target: "18: products may", fill: "#556b2f"},
{source: "18: products may", target: "18: market which may", fill: "#556b2f"},
{source: "18: market which may", target: "18: negative affect on", fill: "#556b2f"},
{source: "18: negative affect on", target: "18: operations", fill: "#556b2f"},
{source: "18: Intellectual ", target: "21: generic competition could", fill: "#8fbc8f"},
{source: "21: generic competition could", target: "21: significant", fill: "#8fbc8f"},
{source: "21: significant", target: "21: downward pressures on", fill: "#8fbc8f"},
{source: "21: downward pressures on", target: "21: prices at which", fill: "#8fbc8f"},
{source: "21: prices at which", target: "21: Company ", fill: "#8fbc8f"},
{source: "21: Company ", target: "21: patented products particularly", fill: "#8fbc8f"},
{source: "21: patented products particularly", target: "21: US Patents ", fill: "#8fbc8f"},
{source: "21: US Patents ", target: "21: applications", fill: "#8fbc8f"},
{source: "21: applications", target: "21: to ScheringPloughs ", fill: "#8fbc8f"},
{source: "21: to ScheringPloughs ", target: "21: significant products", fill: "#8fbc8f"},
{source: "21: significant products", target: "21: ScheringPlough", fill: "#8fbc8f"},
{source: "21: generic competition could", target: "22: Additionally ", fill: "#a57164"},
{source: "22: Additionally ", target: "22: foreign governments", fill: "#a57164"},
{source: "22: foreign governments", target: "22: compulsory", fill: "#a57164"},
{source: "22: compulsory", target: "22: patents may", fill: "#a57164"},
{source: "22: patents may", target: "22: emergencies which could diminish", fill: "#a57164"},
{source: "22: emergencies which could diminish", target: "22: eliminate sales", fill: "#a57164"},
{source: "22: eliminate sales", target: "22: profits from", fill: "#a57164"},
{source: "22: profits from", target: "22: negatively affect", fill: "#a57164"},
{source: "22: negatively affect", target: "22: Companys ", fill: "#a57164"},
{source: "22: Companys ", target: "22: operations", fill: "#a57164"},
{source: "22: Additionally ", target: "24: highly uncertain", fill: "#eee600"},
{source: "24: highly uncertain", target: "24: patent disputes", fill: "#eee600"},
{source: "24: patent disputes", target: "24: pharmaceutical industry", fill: "#eee600"},
{source: "24: highly uncertain", target: "26: patent dispute involving patents", fill: "#c32148"},
{source: "26: patent dispute involving patents", target: "26: third party may preclude", fill: "#c32148"},
{source: "26: third party may preclude", target: "26: commercialization", fill: "#c32148"},
{source: "26: commercialization", target: "26: Companys ", fill: "#c32148"},
{source: "26: Companys ", target: "26: products force", fill: "#c32148"},
{source: "26: products force", target: "26: manufacturing", fill: "#c32148"},
{source: "26: manufacturing", target: "26: negatively", fill: "#c32148"},
{source: "26: patent dispute involving patents", target: "27: Companys ", fill: "#324ab2"},
{source: "27: Companys ", target: "27: DR SCHOLLS FREEZE AWAY ", fill: "#324ab2"},
{source: "27: DR SCHOLLS FREEZE AWAY ", target: "27: wart removal product", fill: "#324ab2"},
{source: "27: wart removal product", target: "27: patent infringement action brought by", fill: "#324ab2"},
{source: "27: patent infringement action brought by", target: "27: party company", fill: "#324ab2"},
{source: "27: party company", target: "27: adverse outcome", fill: "#324ab2"},
{source: "27: adverse outcome", target: "27: action may", fill: "#324ab2"},
{source: "27: action may", target: "27: Companys ", fill: "#324ab2"},
{source: "27: Companys ", target: "27: inability", fill: "#324ab2"},
{source: "27: inability", target: "27: continue manufacturing", fill: "#324ab2"},
{source: "27: Companys ", target: "33: litigation", fill: "#87ceeb"},
{source: "33: litigation", target: "33: ScheringPloughs ", fill: "#87ceeb"},
{source: "33: ScheringPloughs ", target: "33: intellectual property rights always", fill: "#87ceeb"},
{source: "33: intellectual property rights always", target: "33: initiated by third", fill: "#87ceeb"},
{source: "33: initiated by third", target: "33: ScheringPloughs ", fill: "#87ceeb"},
{source: "33: ScheringPloughs ", target: "33: rights as well as by", fill: "#87ceeb"},
{source: "33: rights as well as by", target: "33: ScheringPlough ", fill: "#87ceeb"},
{source: "33: litigation", target: "36: Medicare Prescription Drug Improvement ", fill: "#d71868"},
{source: "36: Medicare Prescription Drug Improvement ", target: "36: prescription", fill: "#d71868"},
{source: "36: prescription", target: "36: individuals", fill: "#d71868"},
{source: "36: Medicare Prescription Drug Improvement ", target: "37: prescription drug benefit", fill: "#fd0e35"},
{source: "37: prescription drug benefit", target: "37: became effective on", fill: "#fd0e35"},
{source: "37: became effective on", target: "37: increased purchasing power", fill: "#fd0e35"},
{source: "37: increased purchasing power", target: "37: negotiating on behalf", fill: "#fd0e35"},
{source: "37: negotiating on behalf", target: "37: recipients", fill: "#fd0e35"},
{source: "37: prescription drug benefit", target: "38: legislation concerning price controls", fill: "#b3446c"},
{source: "38: legislation concerning price controls", target: "38: could affect", fill: "#b3446c"},
{source: "38: could affect", target: "38: Companys ", fill: "#b3446c"},
{source: "38: Companys ", target: "38: legislative", fill: "#b3446c"},
{source: "38: legislative", target: "38: regulatory", fill: "#b3446c"},
{source: "38: regulatory", target: "38: pharmaceutical pricing", fill: "#b3446c"},
{source: "38: pharmaceutical pricing", target: "38: reimbursement health care", fill: "#b3446c"},
{source: "38: reimbursement health care", target: "38: reform initiatives", fill: "#b3446c"},
{source: "38: reform initiatives", target: "38: drug importation legislation involuntary approval", fill: "#b3446c"},
{source: "38: drug importation legislation involuntary approval", target: "38: use consolidation among customers", fill: "#b3446c"},
{source: "38: use consolidation among customers", target: "38: trends toward", fill: "#b3446c"},
{source: "38: trends toward", target: "38: managed care", fill: "#b3446c"},
{source: "38: managed care", target: "38: health care costs containment", fill: "#b3446c"},
{source: "38: legislation concerning price controls", target: "42: The Company ", fill: "#fadfad"},
{source: "42: The Company ", target: "42: cannot predict with certainty", fill: "#fadfad"},
{source: "42: cannot predict with certainty", target: "42: investigations", fill: "#fadfad"},
{source: "42: investigations", target: "42: which may lead", fill: "#fadfad"},
{source: "42: which may lead", target: "42: settlement involving", fill: "#fadfad"},
{source: "42: settlement involving", target: "42: significant monetary award", fill: "#fadfad"},
{source: "42: significant monetary award", target: "42: restrictions on", fill: "#fadfad"},
{source: "42: restrictions on", target: "42: operations", fill: "#fadfad"},
{source: "42: The Company ", target: "43: pricing sales", fill: "#414a4c"},
{source: "43: pricing sales", target: "43: marketing programs", fill: "#414a4c"},
{source: "43: marketing programs", target: "43: arrangements", fill: "#414a4c"},
{source: "43: arrangements", target: "43: participants", fill: "#414a4c"},
{source: "43: participants", target: "43: health care industry", fill: "#414a4c"},
{source: "43: health care industry", target: "43: under increasing scrutiny from federal", fill: "#414a4c"},
{source: "43: under increasing scrutiny from federal", target: "43: regulatory investigative prosecutorial", fill: "#414a4c"},
{source: "43: regulatory investigative prosecutorial", target: "43: administrative entities", fill: "#414a4c"},
{source: "43: pricing sales", target: "44: These ", fill: "#80461b"},
{source: "44: These ", target: "44: Department of Justice ", fill: "#80461b"},
{source: "44: Department of Justice ", target: "44: US Attorneys Offices ", fill: "#80461b"},
{source: "44: These ", target: "45: health care laws under which certain", fill: "#9457eb"},
{source: "45: health care laws under which certain", target: "45: governmental entities", fill: "#9457eb"},
{source: "45: governmental entities", target: "45: common law false", fill: "#9457eb"},
{source: "45: common law false", target: "45: been construed", fill: "#9457eb"},
{source: "45: been construed", target: "45: government entities", fill: "#9457eb"},
{source: "45: government entities", target: "45: significant discretion", fill: "#9457eb"},
{source: "45: health care laws under which certain", target: "48: adverse impact on", fill: "#00bfff"},
{source: "48: adverse impact on", target: "48: Companys ", fill: "#00bfff"},
{source: "48: Companys ", target: "48: operations", fill: "#00bfff"},
{source: "48: operations", target: "48: cash flows financial condition", fill: "#00bfff"},
{source: "48: adverse impact on", target: "START_HERE", fill: "#00bfff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellular_waste_product">Cellular waste product</a></td>
      <td>Cellular waste products are formed as a by-product of cellular respiration, a series of processes and reactions that generate energy for the cell, in the form of ATP. One example of cellular respiration creating cellular waste products are aerobic respiration and anaerobic respiration.\nEach pathway generates different waste products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Podophyllum">Podophyllum</a></td>
      <td>Podophyllum is an herbaceous perennial plant in the family Berberidaceae, described as a genus by Linnaeus in 1753. In the past, several species were included in the genus, but all but one have been transferred to other genera (Dysosma and Sinopodophyllum).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palm_Islands">Palm Islands</a></td>
      <td>The Palm Islands are three man made artificial islands, Palm Jumeirah, Deira Island and Palm Jebel Ali, on the coast of Dubai, United Arab Emirates. The Palm Islands are a major tourist destination within Dubai.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discovery_Channel">Discovery Channel</a></td>
      <td>Discovery Channel (known as The Discovery Channel from 1985 to 1995, and often referred to as simply Discovery) is an American cable channel owned by Warner Bros. Discovery, a publicly traded company run by CEO David Zaslav.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Effective_interest_rate">Effective interest rate</a></td>
      <td>The effective interest rate (EIR), effective annual interest rate, annual equivalent rate (AER) or simply effective rate is the interest rate on a loan or financial product restated from the nominal interest rate and expressed as the equivalent interest rate if compound interest was payable annually in arrears.\nIt is used to compare the interest rates between loans with different compounding periods, such as weekly, monthly, half-yearly or yearly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_generic_and_genericized_trademarks">List of generic and genericized trademarks</a></td>
      <td>The following three lists of generic and genericized trademarks are:\n\nmarks which were originally legally protected trademarks, but have been genericized and have lost their legal status due to becoming generic terms,\nmarks which have been abandoned and are now generic terms\nmarks which are still legally protected as trademarks, at least in some jurisdictions\n\n\n== List of former trademarks that have been genericized ==\nThe following partial list contains marks which were originally legally protected trademarks, but which have subsequently lost legal protection as trademarks by becoming the common name of the relevant product or service, as used both by the consuming public and commercial competitors. These marks were determined in court to have become generic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_places_in_England">List of places in England</a></td>
      <td>Here is a list of places, divided by ceremonial counties of England.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Leahy–Smith_America_Invents_Act">Leahy–Smith America Invents Act</a></td>
      <td>The Leahy–Smith America Invents Act (AIA) is a United States federal statute that was passed by Congress and was signed into law by President Barack Obama on September 16, 2011. The law represents the most significant legislative change to the U.S. patent system since the Patent Act of 1952 and closely resembles previously proposed legislation in the Senate in its previous session (Patent Reform Act of 2009).Named for its lead sponsors, Sen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Triamcinolone">Triamcinolone</a></td>
      <td>Triamcinolone is a glucocorticoid used to treat certain skin diseases, allergies, and rheumatic disorders among others. It is also used to prevent worsening of asthma and COPD. It can be taken in various ways including by mouth, injection into a muscle, and inhalation.Common side effects with long-term use include osteoporosis, cataracts, thrush, and muscle weakness.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Life_Insurance_Corporation">Life Insurance Corporation</a></td>
      <td>Life Insurance Corporation of India (LIC) is an Indian statutory insurance and investment corporation headquartered in the city of Mumbai, India. It is under the ownership of Government of India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Interferon_type_I">Interferon type I</a></td>
      <td>The type-I interferons (IFN) are cytokines which play essential roles in inflammation, immunoregulation, tumor cells recognition, and T-cell responses. In the human genome, a cluster of thirteen functional IFN genes is located at the 9p21.3 cytoband over approximately 400 kb including coding genes for IFNα (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21), IFNω (IFNW1), IFNɛ (IFNE), IFNк (IFNK) and IFNβ (IFNB1), plus 11 IFN pseudogenes.Interferons bind to interferon receptors.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Peginterferon_alfa-2a">Peginterferon alfa-2a</a></td>
      <td>Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Buyers_club">Buyers club</a></td>
      <td>Dallas Buyers Club is a 2013 American biographical drama film written by Craig Borten and Melisa Wallack, and directed by Jean-Marc Vallée. The film tells the story of Ron Woodroof (Matthew McConaughey), an AIDS patient diagnosed in the mid-1980s when HIV/AIDS treatments were under-researched, while the disease was not understood and highly stigmatized.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agriculture_in_Bangladesh">Agriculture in Bangladesh</a></td>
      <td>Agriculture is the largest employment sector in Bangladesh, making up 14.2 percent of Bangladesh's GDP in 2017 and employing about 42.7 percent of the workforce.  The performance of this sector has an overwhelming impact on major macroeconomic objectives like employment generation, poverty alleviation, human resources development, food security, and other economic and social forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acute_decompensated_heart_failure">Acute decompensated heart failure</a></td>
      <td>Acute decompensated heart failure (ADHF) is a sudden worsening of the signs and symptoms of heart failure, which typically includes difficulty breathing (dyspnea), leg or feet swelling, and fatigue. ADHF is a common and potentially serious cause of acute respiratory distress.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collective_Security_Treaty_Organization">Collective Security Treaty Organization</a></td>
      <td>The Collective Security Treaty Organization (CSTO; Russian: Организация Договора о коллективной безопасности, romanized: Organizatsiya Dogovora o kollektivnoy bezopasnosti; Russian: ОДКБ, romanized: ODKB) is an intergovernmental military alliance in Eurasia. The CSTO consists of select post-Soviet states.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Proprietary_estoppel">Proprietary estoppel</a></td>
      <td>Proprietary estoppel is a legal claim, especially connected to English land law, which may arise in relation to rights to use the property of the owner, and may even be effective in connection with disputed transfers of ownership. Proprietary estoppel transfers rights if,\n\nsomeone is given a clear assurance that they will acquire a right over property,\nthey reasonably rely on the assurance, and,\nthey act substantially to their detriment on the strength of the assurance\nit would be unconscionable to go back on the assuranceIf these elements of assurance, reliance and detriment, and unconscionability are present, the usual remedy will be that the property will be transferred to the claimant, if the court views the reliance to warrant a claim in all the circumstances.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Negative_affectivity">Negative affectivity</a></td>
      <td>Negative affectivity (NA), or negative affect, is a personality variable that involves the experience of negative emotions and poor self-concept. Negative affectivity subsumes a variety of negative emotions, including anger, contempt, disgust, guilt, fear, and nervousness.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arbitrage">Arbitrage</a></td>
      <td>Arbitration, a form of alternative dispute resolution (ADR), is a way to resolve disputes outside the judiciary courts. The dispute will be decided by one or more persons (the 'arbitrators', 'arbiters' or 'arbitral tribunal'), which renders the 'arbitration award'.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jazz_Pharmaceuticals">Jazz Pharmaceuticals</a></td>
      <td>Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a biopharmaceutical company based in Ireland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Compulsory_education">Compulsory education</a></td>
      <td>Compulsory education refers to a period of education that is required of all people and is imposed by the government. This education may take place at a registered school or at other places.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_Sentinel_Island">North Sentinel Island</a></td>
      <td>North Sentinel Island is one of the Andaman Islands, an Indian archipelago in the Bay of Bengal which also includes South Sentinel Island. It is home to the Sentinelese, an indigenous people in voluntary isolation who have defended, often by force, their protected isolation from the outside world.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Constitution_Party_(United_States)">Constitution Party (United States)</a></td>
      <td>The Constitution Party, formerly the U.S. Taxpayers' Party until 1999, is  a political party in the United States that promotes a religious conservative view of the principles and intents of the United States Constitution. The party platform is based on originalist interpretations of the Constitution and shaped by principles which it believes were set forth in the Declaration of Independence, the Bill of Rights, the Constitution and the Bible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sunbeam_Products">Sunbeam Products</a></td>
      <td>Sunbeam Products is an American brand that has produced electric home appliances since 1910. Its products have included the Mixmaster mixer, the Sunbeam CG waffle iron, Coffeemaster (1938–1964) and the fully automatic T20 toaster.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Relative_risk">Relative risk</a></td>
      <td>The relative risk (RR) or risk ratio is the ratio of the probability of an outcome in an exposed group to the probability of an outcome in an unexposed group. Together with risk difference and odds ratio, relative risk measures the association between the exposure and the outcome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_jurisdiction">Personal jurisdiction</a></td>
      <td>Personal jurisdiction is a court's jurisdiction over the parties, as determined by the facts in evidence, which bind the parties to a lawsuit, as opposed to subject-matter jurisdiction, which is jurisdiction over the law involved in the suit. Without personal jurisdiction over a party, a court’s rulings or decrees cannot be enforced upon that party, except by comity; i.e., to the extent that the sovereign which has jurisdiction over the party allows the court to enforce them upon that party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/UKG">UKG</a></td>
      <td>The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom (UK) or Britain, is a sovereign country in Europe, off the north-western coast of the continental mainland. It comprises England, Wales, Scotland, and Northern Ireland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Padma_Shri_award_recipients_(2000–2009)">List of Padma Shri award recipients (2000–2009)</a></td>
      <td>Padma Shri Award, India's fourth highest civilian honours – Winners, 2000 – 2009\n\n\n== Recipients ==\n\n\n=== Padma Shri Award recipients in the year 2000 ===\n\n\n=== Padma Shri Award recipients in the year 2001 ===\n\n\n=== Padma Shri Award recipients in the year 2002 ===\n\n\n=== Padma Shri Award recipients in the year 2003 ===\n\n\n=== Padma Shri Award recipients in the year 2004 ===\n\n\n=== Padma Shri Award recipients in the year 2005 ===\n\n\n=== Padma Shri Award recipients in the year 2006 ===\n\n\n=== Padma Shri Award recipients in the year 2007 ===\n\n\n=== Padma Shri Award recipients in the year 2008 ===\n\n\n=== Padma Shri Award recipients in the year 2009 ===\n\n\n== Explanatory notes ==\n\nNon-citizen recipients\nPosthumous recipients\n\n\n== See also ==\nList of Padma Shri award recipients (1954–1959)\nList of Padma Shri award recipients (1960–1969)\nList of Padma Shri award recipients (1970–1979)\nList of Padma Shri award recipients (1980–1989)\nList of Padma Shri award recipients (1990–1999)\nList of Padma Shri award recipients (2010–2019)\nList of Padma Shri award recipients (2020–2029)\n\n\n== References ==\n\n\n== External links ==\nOfficial website\n"Awards &amp; Medals". Ministry of Home Affairs (India).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tagetik">Tagetik</a></td>
      <td>Tagetik develops and sells cloud and on-premises corporate performance management software applications for use by corporate finance teams and their business users.\n\n\n== History ==\nTagetik has headquarters in Lucca, Italy and Stamford, Connecticut.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Marketing_management">Marketing management</a></td>
      <td>Marketing management is the organizational discipline which focuses on the practical application of marketing orientation, techniques and methods inside enterprises and organizations and on the management of a firm's marketing resources and activities.\n\n\n== Structure ==\nMarketing management employs tools from economics and competitive strategy to analyze the industry context in which the firm operates.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Animal">Animal</a></td>
      <td>Animals (also called Metazoa) are multicellular, eukaryotic organisms in the biological kingdom Animalia. With few exceptions, animals consume organic material, breathe oxygen, are able to move, can reproduce sexually, and go through an ontogenetic stage in which their body consists of a hollow sphere of cells, the blastula, during embryonic development.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Private-equity_fund">Private-equity fund</a></td>
      <td>A private-equity fund is a collective investment scheme used for making investments in various equity (and to a lesser extent debt) securities according to one of the investment strategies associated with private equity.\nPrivate equity funds are typically limited partnerships with a fixed term of 10 years (often with annual extensions).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Disparate_impact">Disparate impact</a></td>
      <td>Disparate impact in United States labor law refers to practices in employment, housing, and other areas that adversely affect one group of people of a protected characteristic more than another, even though rules applied by employers or landlords are formally neutral. Although the protected classes vary by statute, most federal civil rights laws protect based on race, color, religion, national origin, and sex as protected traits, and some laws include disability status and other traits as well.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SCHERING PLOUGH CORP      Item 1A Risk Factors             The Company’s future operating results and <font color="blue"><font color="blue"><font color="blue">cash flow</font>s</font> may differ</font>     <font color="blue">materially</font>  from  the  results described in this 10-K due to risks and     <font color="blue">uncertainties</font> related to the Company’s business, including those discussed     below</td>
    </tr>
    <tr>
      <td>In addition, these <font color="blue">factors represent risks</font> and <font color="blue">uncertainties</font> that     could  cause actual results to differ <font color="blue">materially</font> from those implied by     forward-looking statements contained in this report</td>
    </tr>
    <tr>
      <td><font color="blue">Key Company </font><font color="blue">products generate</font> a <font color="blue"><font color="blue">significant</font> amount</font> of the Company’s profits     and <font color="blue"><font color="blue">cash flow</font>s</font>, and any events that <font color="blue">adversely affect</font> the market for its     <font color="blue">leading <font color="blue">products could</font></font> have a material and <font color="blue">negative impact on</font> results of     <font color="blue">operations</font> and <font color="blue"><font color="blue">cash flow</font>s</font></td>
    </tr>
    <tr>
      <td>The Company’s ability to <font color="blue">generate profits</font> and operating <font color="blue">cash flow</font> is     <font color="blue">dependent upon</font> the <font color="blue">increasing <font color="blue">profitability</font></font> of the Company’s <font color="blue">cholesterol</font>     franchise, consisting of <font color="blue">VYTORIN and ZETIA In </font>addition, products such as     CLARINEX, PEG-INTRON, REBETOL, REMICADE, TEMODAR, OTC CLARITIN and NASONEX     accounted  for a material portion of 2005 revenues</td>
    </tr>
    <tr>
      <td>As a result of the     Company’s <font color="blue">dependence on key products</font>, any events that <font color="blue">adversely affect</font> the     markets for these <font color="blue">products could</font> have a <font color="blue"><font color="blue">significant</font> impact on</font> results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These events include loss of patent protection, increased costs     <font color="blue">associated with <font color="blue">manufacturing</font></font>, OTC <font color="blue">availability</font> of the Company’s product or     a <font color="blue">competitive product</font>, the <font color="blue">discovery</font> of <font color="blue">previously unknown</font> side effects,     increased  <font color="blue">competition</font>  from  the  <font color="blue">introduction</font> of new, more <font color="blue">effective</font>     <font color="blue">treatments</font>, and <font color="blue">discontinuation</font> or <font color="blue">removal from</font> the market of the product     for any reason</td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>      More <font color="blue">specifically</font>, the <font color="blue">profitability</font> of the Company’s <font color="blue">cholesterol</font>     <font color="blue">franchise may</font> be <font color="blue">adversely affect</font>ed by the <font color="blue">introduction</font> of <font color="blue">generic forms</font> of     two competing <font color="blue">cholesterol</font> products that <font color="blue">will lose patent protection</font> in 2006</td>
    </tr>
    <tr>
      <td>In addition, generic Flonase (<font color="blue">fluticasone propionate</font>) was approved in 2006     and <font color="blue">may unfavorably impact</font> the <font color="blue">corticosteroid nasal spray market</font></td>
    </tr>
    <tr>
      <td>Past examples of events in <font color="blue">recent years</font> that have <font color="blue">adversely affect</font>ed     the market for <font color="blue">leading products</font> include events that have affected the market     for CLARINEX and PEG-INTRON and REBETOL, <font color="blue">particularly</font> in the US CLARINEX     continues to experience intense <font color="blue">competition</font> in the <font color="blue">prescription</font> US allergy     market after the launch of <font color="blue">CLARITIN OTC </font>and a competing OTC loratadine     product in the <font color="blue">US in December </font>2002 and the <font color="blue">introduction</font> of generic <font color="blue">Allegra     </font>(<font color="blue">fexofenadine</font>) in the <font color="blue">US in September </font>2005</td>
    </tr>
    <tr>
      <td>In addition, as a result of     the <font color="blue">introduction</font> of a competitor’s product for pegylated <font color="blue">interferon</font> and the     <font color="blue">introduction</font>  of <font color="blue">generic ribavirin</font>, the value of PEG-INTRON (pegylated     <font color="blue">interferon</font>) and REBETOL (ribavirin) combination therapy for <font color="blue">hepatitis</font> has     <font color="blue">been severely diminished</font> and earnings and <font color="blue">cash flow</font> have been <font color="blue">materially</font> and     <font color="blue"><font color="blue">negatively</font> impacted</font></td>
    </tr>
    <tr>
      <td>There is a high risk that <font color="blue">funds invested</font> in <font color="blue">research will</font> not generate     financial  returns  because  the  <font color="blue">development</font>  of <font color="blue">novel drugs</font> requires     <font color="blue"><font color="blue">significant</font> expenditures with</font> a <font color="blue">low probability</font> of success</td>
    </tr>
    <tr>
      <td>There is a high rate of <font color="blue">failure inherent</font> in the research to develop     new drugs to <font color="blue">treat diseases</font></td>
    </tr>
    <tr>
      <td>This risk     profile is <font color="blue">compounded by</font> the fact that this research has a <font color="blue">long investment</font>     cycle</td>
    </tr>
    <tr>
      <td>To bring a <font color="blue">pharmaceutical compound from</font> the <font color="blue">discovery</font> phase to market     may take a decade or more and failure can occur at any point in the process,     including later in the process after <font color="blue"><font color="blue">significant</font> funds</font> have <font color="blue">been invested</font></td>
    </tr>
    <tr>
      <td>The Company’s success is <font color="blue">dependent on</font> the <font color="blue">development</font> and marketing of new     products, and <font color="blue">uncertainties</font> in the <font color="blue">regulatory</font> and <font color="blue">approval process may</font>     result in the failure of products to reach the market</td>
    </tr>
    <tr>
      <td>Products that appear promising in <font color="blue">development</font> may fail to <font color="blue">reach market</font>     for <font color="blue">numerous reasons</font>, including the following:         •  findings of in<font color="blue">effective</font>ness or harmful side effects in clinical or     pre-clinical testing;         •  failure to receive the necessary <font color="blue">regulatory</font> approvals, including delays     in the approval of <font color="blue">new products</font> and <font color="blue">new indications</font>;          •  lack of <font color="blue">economic feasibility due</font> to <font color="blue"><font color="blue">manufacturing</font> costs</font> or other     factors; and         •  preclusion from <font color="blue">commercialization</font> by the <font color="blue">proprietary rights</font> of others</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Intellectual </font> </font>property  protection  is an <font color="blue">important contributor</font> to the     Company’s <font color="blue">profitability</font> and <font color="blue">as <font color="blue">patents covering</font></font> the Company’s products     expire or if they are found to be invalid, <font color="blue">generic forms</font> of the Company’s     <font color="blue">products may</font> be introduced to the market, which may have a material and     <font color="blue">negative affect on</font> results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property protection</font> is critical to Schering-Plough’s     ability to <font color="blue">successfully commercialize</font> its products</td>
    </tr>
    <tr>
      <td>Upon the expiration or     the  successful challenge of the Company’s <font color="blue">patents covering</font> a product,     <font color="blue">competitors may introduce generic versions</font> of such products, which may     include the Company’s well-                                         11       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font><font color="blue">established products</font></td>
    </tr>
    <tr>
      <td>Such generic <font color="blue">competition</font> could result in the loss of a     <font color="blue">significant</font> portion of sales or <font color="blue">downward pressures on</font> the <font color="blue">prices at which</font>     the  <font color="blue">Company  </font>offers  formerly  patented products, <font color="blue">particularly</font> in the     <font color="blue">US Patents  </font>and  patent  <font color="blue">applications</font>  relating to Schering-Plough’s     <font color="blue">significant</font> products are of material importance to Schering-Plough</td>
    </tr>
    <tr>
      <td>Additionally,  certain  <font color="blue">foreign <font color="blue">government</font>s</font> have indicated that     <font color="blue">compulsory</font>  licenses to <font color="blue">patents may</font> be granted in the case of national     emergencies, which could diminish or <font color="blue">eliminate sales</font> and <font color="blue">profits from</font> those     regions and <font color="blue"><font color="blue">negatively</font> affect</font> the Company’s results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Patent disputes can be costly to prosecute and defend and <font color="blue">adverse judgments</font>     could  result  in damage awards, increased royalties and other similar     payments and <font color="blue">decreased sales</font></td>
    </tr>
    <tr>
      <td>Patent positions can be <font color="blue">highly uncertain</font> and <font color="blue">patent disputes</font> in the     <font color="blue">pharmaceutical industry</font> are not unusual</td>
    </tr>
    <tr>
      <td>An adverse result in a patent     dispute  involving  the Company’s <font color="blue">patents may</font> lead to a loss of market     <font color="blue">exclusivity</font> and render the Company’s <font color="blue">patents invalid</font></td>
    </tr>
    <tr>
      <td>An adverse result in a     <font color="blue">patent dispute involving patents</font> held by a <font color="blue">third party may preclude</font> the     <font color="blue">commercialization</font> of the Company’s products, force the Company to obtain     licenses  in order to continue <font color="blue">manufacturing</font> or marketing the affected     products,  <font color="blue">negatively</font>  affect  sales of existing products or result in     injunctive  relief and payment of financial remedies</td>
    </tr>
    <tr>
      <td>For example, the     Company’s  product,  DR SCHOLL’S FREEZE AWAY <font color="blue">wart removal product</font>, is     currently the subject of a <font color="blue">patent infringement action brought by</font> a third     <font color="blue">party company</font>, and an <font color="blue">adverse outcome</font> in this <font color="blue">action may</font> result in the     Company’s <font color="blue">inability</font> to continue <font color="blue">manufacturing</font> the product</td>
    </tr>
    <tr>
      <td>Even if the Company is <font color="blue">ultimately successful</font> in a <font color="blue">particular dispute</font>,     the Company may incur substantial costs in defending its patents and other     <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>For example, a <font color="blue"><font color="blue">generic manufacturer</font> may file</font>     an <font color="blue">Abbreviated <font color="blue">New Drug Application </font></font><font color="blue">seeking approval</font> after the expiration of     the applicable data <font color="blue">exclusivity</font> and alleging that one or more of the patents     listed in the innovator’s <font color="blue">New Drug Application </font>are invalid or not infringed</td>
    </tr>
    <tr>
      <td>This <font color="blue">allegation</font> is <font color="blue">commonly known as</font> a <font color="blue">Paragraph IV </font><font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">innovator then</font> has the ability to <font color="blue">file suit against</font> the <font color="blue">generic manufacturer</font>     to enforce its patents</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, <font color="blue">generic manufacturer</font>s have used     <font color="blue">Paragraph IV </font><font color="blue">certification</font>s extensively to <font color="blue">challenge patents on</font> a <font color="blue">wide array</font>     of <font color="blue">innovative pharmaceuticals</font>, and it is anticipated that this trend will     continue</td>
    </tr>
    <tr>
      <td>The  potential  for  <font color="blue">litigation</font> regarding Schering-Plough’s     <font color="blue">intellectual property rights</font> always exists and may be <font color="blue">initiated by third</font>     parties  attempting to abridge Schering-Plough’s rights, as well as by     Schering-Plough in protecting its rights</td>
    </tr>
    <tr>
      <td>US and foreign <font color="blue">regulations</font>, including those <font color="blue">establishing</font> the Company’s     ability to price products, may <font color="blue"><font color="blue">negatively</font> affect</font> the Company’s sales and     <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">faces increased pricing pressure</font> in the US and abroad     from <font color="blue">managed care</font> <font color="blue">organizations</font>, <font color="blue">institutions</font> and <font color="blue">government</font> agencies and     programs  that  could <font color="blue"><font color="blue">negatively</font> affect</font> the Company’s sales and profit     margins</td>
    </tr>
    <tr>
      <td>For  example, the <font color="blue">Medicare Prescription Drug Improvement </font>and     Modernization  Act  of  2003  contains a <font color="blue">prescription</font> drug benefit for     <font color="blue">individuals</font> who are eligible for Medicare</td>
    </tr>
    <tr>
      <td>The <font color="blue">prescription</font> drug benefit     became <font color="blue">effective</font> on January 1, 2006, and it is anticipated that it may     result in <font color="blue">increased purchasing power</font> of those <font color="blue">negotiating on behalf</font> of     Medicare <font color="blue">recipients</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">legislation concerning price controls</font>, other trends     that <font color="blue">could affect</font> the Company’s business include <font color="blue">legislative</font> or <font color="blue">regulatory</font>     action relating to <font color="blue">pharmaceutical pricing</font> and <font color="blue">reimbursement</font>, health care     <font color="blue">reform initiatives</font> and drug importation legislation, involuntary approval of     medicines for OTC use, consolidation among customers, and <font color="blue">trends toward</font>     <font color="blue">managed care</font> and <font color="blue">health care costs containment</font></td>
    </tr>
    <tr>
      <td>As a result <font color="blue">of the US </font><font color="blue">government</font>’s efforts to reduce <font color="blue">Medicaid     </font>expenses, <font color="blue">managed care</font> <font color="blue">organizations</font> continue to grow in influence and the     Company <font color="blue">faces increased pricing pressure</font> as <font color="blue">managed care</font> <font color="blue">organizations</font>     continue to <font color="blue">seek price discounts with respect</font> to the Company’s products</td>
    </tr>
    <tr>
      <td>In  the  <font color="blue">international</font>  markets, cost control methods including     <font color="blue">restrictions</font> on physician <font color="blue">prescription</font> levels and patient <font color="blue"><font color="blue">reimbursement</font>s</font>,     emphasis on greater use of generic drugs, and across the board price cuts     may decrease revenues <font color="blue">international</font>ly</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>There are material <font color="blue">pending <font color="blue">investigations</font> against</font> the Company, the outcome     of which could include the <font color="blue">commencement</font> of civil and/or criminal <font color="blue">proceedings</font>     involving the imposition of substantial fines, penalties and injunctive or     <font color="blue">administrative</font> remedies, including exclusion from <font color="blue">government</font> <font color="blue">reimbursement</font>     programs</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot predict with certainty</font> the outcome of the pending     <font color="blue">investigations</font> to which it is subject, any of <font color="blue">which may lead</font> to a judgment     or <font color="blue">settlement involving</font> a <font color="blue">significant</font> monetary award or <font color="blue">restrictions</font> on its     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The pricing, sales and <font color="blue">marketing programs</font> and <font color="blue">arrangements</font>, and     related business practices of the Company and other <font color="blue">participants</font> in the     <font color="blue">health care industry</font> are <font color="blue">under increasing scrutiny from federal</font> and state     <font color="blue">regulatory</font>, investigative, prosecutorial and <font color="blue">administrative</font> entities</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>entities include the <font color="blue">Department of Justice </font>and its US Attorney’s Offices,     the  Office of Inspector General of the Department of Health and Human     Services, the FDA, the Federal Trade Commission and various state Attorneys     General offices</td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">health care laws under which certain</font> of these     <font color="blue">government</font>al entities operate, including the federal and state anti-kickback     statutes and statutory and <font color="blue">common law false</font> claims laws, have <font color="blue">been construed</font>     broadly  by  the courts and permit the <font color="blue">government</font> entities to exercise     <font color="blue">significant</font> discretion</td>
    </tr>
    <tr>
      <td>In the event that any of those <font color="blue">government</font>al entities     believes that wrongdoing has occurred, one or more of <font color="blue">them could institute</font>     civil  or  criminal  <font color="blue">proceedings</font>,  which,  if  instituted and resolved     unfavorably, could subject the Company to substantial fines, penalties and     injunctive or <font color="blue">administrative</font> remedies, including exclusion from <font color="blue">government</font>     <font color="blue">reimbursement</font>  programs</td>
    </tr>
    <tr>
      <td>The  Company <font color="blue">also cannot predict whether</font> any     <font color="blue">investigations</font> will affect its <font color="blue">marketing practices</font> or sales</td>
    </tr>
    <tr>
      <td>Any such result     could have a material <font color="blue">adverse impact on</font> the Company’s results of <font color="blue">operations</font>,     <font color="blue"><font color="blue">cash flow</font>s</font>, financial condition, or its business</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless  </font>of  the merits or outcomes of these <font color="blue">investigations</font>,     <font color="blue">government</font> <font color="blue">investigations</font> are costly, divert management’s attention from the     Company’s business and may result in substantial damage to the Company’s</td>
    </tr>
  </tbody>
</table>